U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

D-2-hydroxyglutaric aciduria

MedGen UID:
322192
Concept ID:
C1833429
Disease or Syndrome
Synonyms: D-2-HGA; D-2-Hydroxyglutaric Acidemia
SNOMED CT: D-2-hydroxyglutaric aciduria (237960000); D-2(OH) glutaric aciduria (237960000)
Modes of inheritance:
Autosomal recessive inheritance
MedGen UID:
141025
Concept ID:
C0441748
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in individuals with two pathogenic alleles, either homozygotes (two copies of the same mutant allele) or compound heterozygotes (whereby each copy of a gene has a distinct mutant allele).
Autosomal dominant inheritance
MedGen UID:
141047
Concept ID:
C0443147
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in heterozygotes. In the context of medical genetics, an autosomal dominant disorder is caused when a single copy of the mutant allele is present. Males and females are affected equally, and can both transmit the disorder with a risk of 50% for each child of inheriting the mutant allele.
 
HPO: HP:0012321
Monarch Initiative: MONDO:0010924
OMIM® Phenotypic series: PS600721
Orphanet: ORPHA79315

Definition

An increased concentration of 2-hydroxyglutaric acid in the urine. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVD-2-hydroxyglutaric aciduria

Conditions with this feature

D-2-hydroxyglutaric aciduria 2
MedGen UID:
462259
Concept ID:
C3150909
Disease or Syndrome
2-hydroxyglutaric aciduria is a condition that causes progressive damage to the brain. The major types of this disorder are called D-2-hydroxyglutaric aciduria (D-2-HGA), L-2-hydroxyglutaric aciduria (L-2-HGA), and combined D,L-2-hydroxyglutaric aciduria (D,L-2-HGA).\n\nThe main features of D-2-HGA are delayed development, seizures, weak muscle tone (hypotonia), and abnormalities in the largest part of the brain (the cerebrum), which controls many important functions such as muscle movement, speech, vision, thinking, emotion, and memory. Researchers have described two subtypes of D-2-HGA, type I and type II. The two subtypes are distinguished by their genetic cause and pattern of inheritance, although they also have some differences in signs and symptoms. Type II tends to begin earlier and often causes more severe health problems than type I. Type II may also be associated with a weakened and enlarged heart (cardiomyopathy), a feature that is typically not found with type I.\n\nL-2-HGA particularly affects a region of the brain called the cerebellum, which is involved in coordinating movements. As a result, many affected individuals have problems with balance and muscle coordination (ataxia). Additional features of L-2-HGA can include delayed development, seizures, speech difficulties, and an unusually large head (macrocephaly). Typically, signs and symptoms of this disorder begin during infancy or early childhood. The disorder worsens over time, usually leading to severe disability by early adulthood.\n\nCombined D,L-2-HGA causes severe brain abnormalities that become apparent in early infancy. Affected infants have severe seizures, weak muscle tone (hypotonia), and breathing and feeding problems. They usually survive only into infancy or early childhood.
D-2-hydroxyglutaric aciduria 1
MedGen UID:
463405
Concept ID:
C3152055
Disease or Syndrome
D-2-hydroxyglutaric aciduria is a neurometabolic disorder first described by Chalmers et al. (1980). Clinical symptoms include developmental delay, epilepsy, hypotonia, and dysmorphic features. Mild and severe phenotypes were characterized (van der Knaap et al., 1999). The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and, often, cardiomyopathy. The mild phenotype has a more variable clinical presentation. Genetic Heterogeneity of D-2-Hydroxyglutaric Aciduria D-2-hydroxyglutaric aciduria-2 (D2HGA2; 613657) is caused by heterozygous mutation in the mitochondrial isocitrate dehydrogenase-2 gene (IDH2; 147650) on chromosome 15q26.

Professional guidelines

PubMed

Gibson KM, ten Brink HJ, Schor DS, Kok RM, Bootsma AH, Hoffmann GF, Jakobs C
Pediatr Res 1993 Sep;34(3):277-80. doi: 10.1203/00006450-199309000-00007. PMID: 8134166

Recent clinical studies

Etiology

Korman SH, Salomons GS, Gutman A, Brooks R, Jakobs C
Neuropediatrics 2004 Jun;35(3):151-6. doi: 10.1055/s-2004-817905. PMID: 15248096
Clarke NF, Andrews I, Carpenter K, Jakobs C, van der Knaap MS, Kirk EP
Am J Med Genet A 2003 Aug 1;120A(4):523-7. doi: 10.1002/ajmg.a.20120. PMID: 12884432
Kwong KL, Mak T, Fong CM, Poon KH, Wong SN, So KT
Acta Paediatr 2002;91(6):716-8. doi: 10.1080/080352502760069188. PMID: 12162609
van der Knaap MS, Jakobs C, Hoffmann GF, Nyhan WL, Renier WO, Smeitink JA, Catsman-Berrevoets CE, Hjalmarson O, Vallance H, Sugita K, Bowe CM, Herrin JT, Craigen WJ, Buist NR, Brookfield DS, Chalmers RA
Ann Neurol 1999 Jan;45(1):111-9. doi: 10.1002/1531-8249(199901)45:1<111::aid-art17>3.0.co;2-n. PMID: 9894884
Gibson KM, ten Brink HJ, Schor DS, Kok RM, Bootsma AH, Hoffmann GF, Jakobs C
Pediatr Res 1993 Sep;34(3):277-80. doi: 10.1203/00006450-199309000-00007. PMID: 8134166

Diagnosis

Cansever MŞ, Öztekin N, Kıykım E, Zübarioğlu T, Aktuğlu Zeybek AÇ
J Sep Sci 2023 Aug;46(16):e2300145. Epub 2023 Jun 3 doi: 10.1002/jssc.202300145. PMID: 37269210
Murphey K, George PE, Pencheva B, Porter CC, Wechsler SB, Gambello MJ, Li H
Am J Med Genet A 2022 Sep;188(9):2707-2711. Epub 2022 Jul 4 doi: 10.1002/ajmg.a.62891. PMID: 35785415
Wu B, Li Z, Kang Z, Ma C, Song H, Lu F, Zhu Z
Biosensors (Basel) 2022 Jan 25;12(2) doi: 10.3390/bios12020066. PMID: 35200327Free PMC Article
Struys EA
J Inherit Metab Dis 2006 Feb;29(1):21-9. doi: 10.1007/s10545-006-0317-9. PMID: 16601864
Nyhan WL, Shelton GD, Jakobs C, Holmes B, Bowe C, Curry CJ, Vance C, Duran M, Sweetman L
J Child Neurol 1995 Mar;10(2):137-42. doi: 10.1177/088307389501000216. PMID: 7782605

Therapy

Geoerger B, Schiff M, Penard-Lacronique V, Darin N, Saad SM, Duchon C, Lamazière A, Desmons A, Pontoizeau C, Berlanga P, Ducassou S, Yen K, Su M, Schenkein D, Ottolenghi C, De Botton S
Nat Med 2023 Jun;29(6):1358-1363. Epub 2023 May 29 doi: 10.1038/s41591-023-02382-9. PMID: 37248298
Srinivasan A, Zhou Y, Scordino T, Prabhu S, Wierenga A, Simon G, Wierenga KJ, Thompson J, Shah R, Sinha AA
Pediatr Hematol Oncol 2020 Aug;37(5):431-437. Epub 2020 Mar 13 doi: 10.1080/08880018.2020.1737284. PMID: 32166993

Prognosis

Thirumal Kumar D, Jerushah Emerald L, George Priya Doss C, Sneha P, Siva R, Charles Emmanuel Jebaraj W, Zayed H
Metab Brain Dis 2018 Oct;33(5):1699-1710. Epub 2018 Jul 9 doi: 10.1007/s11011-018-0278-3. PMID: 29987523
Vissers LE, Fano V, Martinelli D, Campos-Xavier B, Barbuti D, Cho TJ, Dursun A, Kim OH, Lee SH, Timpani G, Nishimura G, Unger S, Sass JO, Veltman JA, Brunner HG, Bonafé L, Dionisi-Vici C, Superti-Furga A
Am J Med Genet A 2011 Nov;155A(11):2609-16. doi: 10.1002/ajmg.a.34325. PMID: 22025298
Clarke NF, Andrews I, Carpenter K, Jakobs C, van der Knaap MS, Kirk EP
Am J Med Genet A 2003 Aug 1;120A(4):523-7. doi: 10.1002/ajmg.a.20120. PMID: 12884432
Kwong KL, Mak T, Fong CM, Poon KH, Wong SN, So KT
Acta Paediatr 2002;91(6):716-8. doi: 10.1080/080352502760069188. PMID: 12162609
Geerts Y, Renier WO, Bakkeren J, de Jong J
J Neurol Sci 1996 Nov;143(1-2):166-9. doi: 10.1016/s0022-510x(96)00179-7. PMID: 8981317

Clinical prediction guides

Geoerger B, Schiff M, Penard-Lacronique V, Darin N, Saad SM, Duchon C, Lamazière A, Desmons A, Pontoizeau C, Berlanga P, Ducassou S, Yen K, Su M, Schenkein D, Ottolenghi C, De Botton S
Nat Med 2023 Jun;29(6):1358-1363. Epub 2023 May 29 doi: 10.1038/s41591-023-02382-9. PMID: 37248298
Rodrigues DGB, de Moura Coelho D, Sitta Â, Jacques CED, Hauschild T, Manfredini V, Bakkali A, Struys EA, Jakobs C, Wajner M, Vargas CR
Toxicol In Vitro 2017 Aug;42:47-53. Epub 2017 Apr 7 doi: 10.1016/j.tiv.2017.04.006. PMID: 28396261
Kranendijk M, Struys EA, Gibson KM, Wickenhagen WV, Abdenur JE, Buechner J, Christensen E, de Kremer RD, Errami A, Gissen P, Gradowska W, Hobson E, Islam L, Korman SH, Kurczynski T, Maranda B, Meli C, Rizzo C, Sansaricq C, Trefz FK, Webster R, Jakobs C, Salomons GS
Hum Mutat 2010 Mar;31(3):279-83. doi: 10.1002/humu.21186. PMID: 20020533
Das AM
Mol Genet Metab 2003 Jun;79(2):71-82. doi: 10.1016/s1096-7192(03)00069-6. PMID: 12809636
van der Knaap MS, Jakobs C, Hoffmann GF, Nyhan WL, Renier WO, Smeitink JA, Catsman-Berrevoets CE, Hjalmarson O, Vallance H, Sugita K, Bowe CM, Herrin JT, Craigen WJ, Buist NR, Brookfield DS, Chalmers RA
Ann Neurol 1999 Jan;45(1):111-9. doi: 10.1002/1531-8249(199901)45:1<111::aid-art17>3.0.co;2-n. PMID: 9894884

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...